1. Solar Industries India:
ICICI Direct maintains its ‘Buy’ call on this industrial explosives manufacturer, with a target price of Rs 20,200, an upside of 11.5%. Analysts Vijay Goel and Kush Bhandari are optimistic, as the company rapidly expands its defence business. The company is seeing strong order execution, rising exports, and growth in advanced ammunition and drone systems.
Solar Industries delivered a robust Q4FY26. Revenue surged 40.9% YoY, helped by defence and export demand. Defence revenue more than doubled, while export revenue grew 32%.
Management expects revenue of Rs 14,000 crore in FY27, maintaining 27-28% EBITDA margins. The company has a Rs 18,000 crore defence order backlog, driven by demand for ammunition and warfare systems. Solar Industries is also expanding its global footprint in Africa, Southeast Asia, and Australia, and investing in new facilities.
Goel and Bhandari project defence as the company's main growth driver in the medium term. They estimate revenue and profit will grow 30% and 32% annually, respectively, from FY27-28. Analysts also expect a recovery in the domestic explosives business, which remained weak in FY26. They believe growth will improve in FY27 on the back of improving mining activity & housing demand, and higher infrastructure spending.
2. CreditAccess Grameen:
Deven Choksey retains its ‘Buy’ call on this microfinance lender, with a target price of Rs 1,660, a 26.7% upside. CreditAccess Grameen delivered good Q4FY26 results, with net interest income (NII) rising 19.6% YoY. Net profit surged 7.2 times, due to a lower base and improving asset quality. Assets under management (AUM) jumped 14%, driven by higher loan disbursements.
Analysts Neel Mehta and Maahir Mani expect normalised asset quality and scaled-up retail finance to drive earnings recovery. The company added fewer risky loans, signalling a turning of the credit cycle. Retail finance, which accounts for 18.1% of AUM, acts as a major earnings driver; management targets a 25% share by FY27. Its digital app, Grameen Mahi, also reportedly lowers collection costs and improves underwriting, building a durable competitive edge.
Management estimates 20-25% AUM growth with net interest margins of around 13% in FY27. Mehta and Mani expect the company to deliver 54% net profit and 13.8% revenue CAGRs through FY28, boosted by lower credit costs and improved operating efficiencies.
3. CCL Products India:
Axis Direct maintains its ‘Buy’ rating on this coffee manufacturer, with a target price of Rs 1,280, an upside of 17.5%. Analysts Suhanee Shome and Urmi Shah are bullish following a positive Q4FY26, fuelled by higher sales volumes, steady exports, and solid growth in its branded business. Revenue soared 46.5% YoY, and EBITDA increased 17.5%. However, margins tightened due to higher coffee prices and expansion costs.
Management reports its Continental brand is now India's third-largest coffee brand, holding the second spot in some southern markets. The company is also gaining market share in Delhi and Mumbai as it expands beyond South India. Branded coffee volumes grew 30% in FY26, and management anticipates momentum to continue. They also guide for around 15% growth in volumes and EBITDA for FY27. Coffee prices are estimated to soften after the Brazilian harvest, potentially boosting future margins.
Shome and Shah believe CCL Products is in a great position to capture rising global demand for premium coffee. They cite the company’s manufacturing base in India and Vietnam, a stronger balance sheet, and impressive branded growth as key strengths.
4. Global Health:
Prabhudas Lilladher maintains its ‘Buy’ rating on this hospital chain, with a target price of Rs 1,450, an upside of 16.9%. Analysts Param Desai and Sanketa Kohale believe growth at its Lucknow and Patna hospitals and better performance in Noida will drive earnings over the next two years.
Global Health's Q4FY26 revenue rose 24.5% YoY, thanks to patient growth. Inpatient volumes climbed 24%, and outpatient volumes grew 27%. Average revenue per occupied bed (ARPOB) improved 5%, driven by a better case mix and shorter patient stays.
Management reports the Noida unit's ramp-up is on track, with narrowing losses and expected breakeven by H2FY27. The company plans to add about 3,190 beds over 3–4 years via new projects and expansions across North India. Management guides FY27 capex at Rs 850 crore and expects mature hospitals to improve profitability through better operating leverage, oncology expansion, and higher government affiliations.
Desai and Kohale estimate EBITDA to grow about 24% annually from FY27-28. Lucknow's recovery, Noida's expansion, and consistent growth from established hospitals will drive this. They expect better occupancy, ARPOB growth, and new market entry to support medium-term earnings.
5. Senores Pharmaceuticals:
BOB Capital Markets maintains its ‘Buy’ rating on this small-cap pharma company, with a target price of Rs 1,250, an upside of 18.3%. Analyst Foram Parekh remains positive after Senores Pharma delivered a healthy Q4FY26. Revenue rose 53% YoY, driven by growth across regulated markets, emerging markets, and branded generics. Regulated markets jumped 83%, boosted by new product launches and contributions from its arm, Apnar Pharma. Emerging markets also rose 26%.
Management states that regulated markets remain the core growth engine, backed by an extensive pipeline of abbreviated new drug application approvals and launches. The company expects about 30 launches over the next 6–8 quarters, driving momentum in the US market. Management also projects growth in emerging markets, supported by expanding registrations and product additions. They foresee gradual margin improvement as the company scales.
Parekh expects the company to sustain this earnings growth over FY27-29. An expanding regulated market presence, global diversification, and improved operational leverage will fuel this. She adds that free cash flow is anticipated to turn positive starting FY27.
Note: These recommendations are from various analysts and are not recommendations by Trendlyne.
(You can find all analyst picks here)